Global

3 August 2009

31 July 2009

Statins should be given to people with high blood pressure or diabetes, even if they don?t have heart disease, according to a study published in the British Medical Journal.

16 July 2009

08 July 2009

UK Health Institute leaves guidance unchanged in case against Eisai and Pfizer; more research on NICE methodology needed.

Pharma is wrestling to understand the emerging markets will be the engine of growth for future sales.

12 June 2009

9 June 2009

A 45-minute webinar on assay and system validation hosted by Marian Kelley, contributing author of DeSilva white paper, on behalf of Gyros AB.

New prediction reflects incremental pressure from economic crisis.

4 June 2009

1 June 2009

1 June 2009

Pharm Exec Europe's Gerhard Symons speaks to Andrew Jones, a senior pharmaceutical analyst with the firm, about the value of introducing a "risk radar" to your organization.

A new report by the Royal College of Physicians breaks down the reasons why patients are disillusioned about access to medicines, and documents a steady growth in the lack of trust between industry and the NHS. More importantly, it gives recommendations on how to solve the problems.

It could be the end of the road for the UK's biotech firms if drastic action isn't taken soon.

EC proposal loosens restrictions on drug packaging and information dissemination.

In Europe, it's different strokes for different folks at the top regulatory agencies

Tensions mount as stakeholders in the UK health industry attempt to work out drug cost problems

In order to take a big step forward, GSK looks to employ smaller licensing deals and business units

Britain's new approach to drug pricing isn't as bad as the industry feared.

Can ceasing trade sales and finding funding help UK biotechs became an industry in their own right?

UK agency takes the heat for slow evaluations and failing to consider societal benefits of new drugs

The first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked-the more money one has, the healthier one is likely to be.

Tainted batches of Viracept pulled from European shelves.

Says Roche UK CEO John Melville: "There is little difference in the incidence of cancer, in broad terms, across Europe, but cancer survival is very different"

Stakeholders worry that less competition among drug suppliers in the United Kingdom could mean higher prices and a bigger bill for the National Health Service

The UK has benefited from the stem-cell debate in the US. Several scientists have fled to Europe's more favorable regulatory stance.

A free flow of cheap counterfeits eclipses the ability of local manufacturers to create new products.